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Background: Repositioning of existing drugs has been suggested as a fast track for developing new anti-malarial
agents. The compound libraries of GlaxoSmithKline (GSK), Pfizer and AstraZeneca (AZ) comprising drugs that
have undergone clinical studies in other therapeutic areas, but not achieved approval, and a set of US Food and
Drug Administration (FDA)-approved drugs and other bio-actives were tested against Plasmodium falciparum
blood stages.
Methods: Molecules were tested initially against erythrocytic co-cultures of P. falciparum to measure proliferation
inhibition using one of the following methods: SYBR®I dye DNA staining assay (3D7, K1 or NF54 strains); [3H]
hypoxanthine radioisotope incorporation assay (3D7 and 3D7A strain); or 4’,6-diamidino-2-phenylindole (DAPI)
DNA imaging assay (3D7 and Dd2 strains). After review of the available clinical pharmacokinetic and safety data,
selected compounds with low μM activity and a suitable clinical profile were tested in vivo either in a Plasmodium
berghei four-day test or in the P. falciparum Pf3D70087/N9 huSCID ‘humanized’ mouse model.
Results: Of the compounds included in the GSK and Pfizer sets, 3.8% (9/238) had relevant in vitro anti-malarial
activity while 6/100 compounds from the AZ candidate drug library were active. In comparison, around 0.6%
(24/3,800) of the FDA-approved drugs and other bio-actives were active. After evaluation of available clinical
data, four investigational drugs, active in vitro were tested in the P. falciparum humanized mouse model:
UK-112,214 (PAF-H1 inhibitor), CEP-701 (protein kinase inhibitor), CEP-1347 (protein kinase inhibitor), and PSC-833
(p-glycoprotein inhibitor). Only UK-112,214 showed significant efficacy against P. falciparum in vivo, although at
high doses (ED90 131.3 mg/kg [95% CI 112.3, 156.7]), and parasitaemia was still present 96 hours after treatment
commencement. Of the six actives from the AZ library, two compounds (AZ-1 and AZ-3) were marginally
efficacious in vivo in a P. berghei model.
Conclusions: Repositioning of existing therapeutics in malaria is an attractive proposal. Compounds active in vitro
at μM concentrations were identified. However, therapeutic concentrations may not be effectively achieved in mice
or humans because of poor bio-availability and/or safety concerns. Stringent safety requirements for anti-malarial
drugs, given their widespread use in children, make this a challenging area in which to reposition therapy.
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Effective anti-malarial treatment with artemisinin-based
combination therapy (ACT) has been critical for support-
ing and consolidating recent gains in malaria control, with
reductions in the number of cases and in mortality [1].
Malaria elimination is becoming a reality for some coun-
tries [2], and strategies for global malaria eradication are
now being considered [3,4]. This will require new drug
regimens with improvements in cost, simplicity and effi-
cacy against resistant strains [5]. In particular, the emer-
gence of Plasmodium falciparum strains that are tolerant
to artemisinin in the Thai-Cambodia border area is of
great concern [6]. This not only has direct implications for
artemisinin therapy, but promotes the selection of strains
resistant to partner drugs.
New anti-malarial drugs are needed urgently [7]. Recent
improvements in cell-based screening technology have led
to over 20,000 new starting points in medicinal chemistry
[8-10], and the great majority of these data are open
access [11]. This has led to a whole series of new mole-
cules in preclinical development [12]. For example, one
series, the spiroindolones, has entered early clinical studies
only five years after the initiation of screening [13].
In general, however, malaria projects take much longer
than five years to go from discovery to having a clinical
candidate. Sometimes this is because of technical chal-
lenges, but more often because of lack of funding or
other resources and the attrition rates are high. It is
clearly important to search for new approaches to make
this process more efficient. An alternative approach is
that of drug repositioning or repurposing. Most simply,
this is taking a molecule that has been developed for one
indication and showing its utility in another. Although
the concept is widely discussed as an attractive drug
development strategy, meaningful published data on its
success rate and the factors determining that success
are limited.
Starting with a molecule that has already undergone
clinical trials in another indication provides several
potential advantages. The clinical safety profile will be
understood, and safe therapeutic doses will have been
established. Importantly, human pharmacokinetic data
will exist and provide some indication of whether thera-
peutic concentrations in the new indication can be
achieved safely and maintained in patients. In addition,
there are regulatory fast track processes, such as the US
Food and Drug Administration (FDA) 505 (b) (2) process,
where the applicant can rely on data from the studies
done by others (with or without the right to reference
them) to progress the compound for the new indication.
This has acted as a spur to finding new activities of old
molecules [14].
Programmes to identify new clinical activities of existing
medicines have been conducted in many therapeuticareas, such as oncology [15] and for orphan diseases [16],
where there is often an extremely high and specific unmet
medical need. Approaches have also been successful in in-
fectious disease, such as tuberculosis [17], schistosomiasis
[18] and onchocerciasis [19]. In human African trypano-
somiasis, fexinidazole was not so much repositioned as
rediscovered following compound mining efforts of more
than 700 new and existing nitroheterocycles; efficacy in
animal models was initially reported in the 1980s [20,21].
In malaria, there have also been initiatives in drug
repositioning. Screening a library of 2,687 compounds
containing 1,937 FDA-registered medicines and 750 other
molecules in clinical development identified astemizole
(a histamine H1 antagonist) as the most promising
compound, with good activity against P. falciparum
blood stages [22]. Unfortunately, this drug was withdrawn
because of side effects linked to QTc prolongation, so
could not be repositioned as an anti-malarial. A smaller
collection of 1,037 existing drugs was tested in an assay
for activity against Plasmodium liver stages and decoqui-
nate was identified as a potent inhibitor both in vitro and
in vivo [23,24]. As this drug has a veterinary indication, no
human safety information is available, but it remains an
interesting possibility.
A further potential source of drugs for repositioning is
those molecules where clinical development has been
discontinued before approval. Of particular interest are
drugs that did not achieve efficacy in their proposed
indication even though a safe plasma exposure could be
obtained in humans. However, it may be difficult to
obtain information on such drugs, or gain access to
physical samples of them.
In the course of screening large compound collections
from pharmaceutical and biotechnology companies
against the blood stages of P. falciparum [8-10], it was
apparent that compounds that had progressed to clinical
development were often excluded from the test set. The
studies outlined in this paper aimed to specifically iden-
tify and test molecules that were not clinically available,
but for which some clinical development activity had
been conducted. Existing libraries of FDA-approved
drugs and some selected bio-actives were also tested,
with particular emphasis on antineoplastic and antiretro-
viral agents. Any compounds showing low micromolar
activity and with a suitable pharmacokinetic and safety
profile were further evaluated in vivo.
Methods
Study design
Figure 1 shows the Medicines for Malaria Venture (MMV)
decision algorithm for the repositioning of drugs for the
treatment of P. falciparum malaria [25,26]. In the studies
reported here, compounds were tested in vitro against
P. falciparum and those with significant in vitro activity
Figure 1 Medicines for Malaria Venture decision algorithm for repositioning medicines against malaria. The red text indicates the
approximate amounts of money and time that are needed to conduct the studies indicated in the boxes. TPP1: Single exposure radical cure for
the treatment of acute uncomplicated malaria in children and adults [25]. TPP2: Non-artemisinin-based combination therapy (NACT) for treatment
of acute uncomplicated malaria in children and adults [26].
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ical safety and human pharmacokinetics (due diligence).
Compounds that were active in vitro and with an accept-
able safety/pharmacokinetic profile were progressed to
in vivo testing. Compound testing sets and assay methods
are summarized in Table 1.
Compounds screened
An initial set of around 3,500 compounds was assembled
and tested by St Jude’s Children’s Research Hospital
(SJCRH). This comprised a library of approximately 800
FDA-approved drugs registered up to the year 2008, plus
about 2,700 bio-active compounds sourced from the
complete Prestwick, Sigma-Lopac and Merck Sharp &
Dohme (MSD) libraries. Subsequently, a smaller set of
296 FDA-approved drugs updated for 2009 was tested as
well as a small library of 47 ‘antiproliferative’ compounds
to further assess targets related to protein kinase inhibitors,
antineoplastic and antiretroviral agents. Compounds were
not deselected based on known toxicities in order to pro-
vide information that could inform the identification and
selection of related compounds in development, which
could be sourced subsequently. In total, the consolidated
test set included approximately 3,800 unique compounds,
excluding known anti-malarial drugs. Compounds for the
SJCRH screens were sourced firstly from the SJCRH drugrepository or, if not available, were obtained from com-
mercial vendors or resynthesized. All supplied compounds
were assured by the vendor as >90% pure with quality
control data provided and were verified internally at
SJCRH after plating.
An initial search of the GlaxoSmithKline (GSK) clinical
development pipeline on a commercially available data-
base (Thomson Pharma) revealed around 100 compounds
that had been taken into clinical development and subse-
quently been discontinued. Excluding those molecules
that had already been screened against P. falciparum in
the GSK discovery library [9], samples were obtained from
GSK for 63 new compounds. GSK verified samples for
purity and activity, and conducted the in vitro testing for
this compound set.
Pfizer Inc were also approached, and offered to
screen their STLAR library of 176 drugs, comprised
mainly of pre-Phase III discontinued clinical candi-
dates, though Phase III data were available for a few
compounds. There were no approved drugs or active
clinical candidates in the set. Pfizer provided samples
verified for purity and activity. First, the compound
set was tested in vitro using high-throughput screen-
ing (HTS) by Discovery Biology, Griffith University,
Nathan, Australia with subsequent EC50 determination
by Pfizer in-house.





In vitro testing method No. hits (%) No. tested
in vivo*
~3,800 • 800 FDA-approved drugs (2008) SJCRH • SYBR® I dye DNA staining assay 24 (0.6) 1
• 2,700 bio-actives (Prestwick,
Sigma-Lopac, and MSD)
• P. falciparum 3D7 and K1
• 296 FDA-approved drugs (2009)
• 47 ‘anti-proliferative’ compounds
63 GSK discontinued clinical candidates GSK • Whole-cell [3H] hypoxanthine radioisotope
incorporation
4 (6.4) 0
• P. falciparum 3D7A
176 Pfizer STLAR library of discontinued
clinical candidates
Discovery biology • HTS screen using DAPI DNA imaging
assay with P. falciparum 3D7 and Dd2
5 (2.8) 1
Pfizer • EC50 determined using SYBR® I dye DNA
staining assay with P. falciparum 3D7 and K1
100 AstraZeneca discontinued clinical
candidates
AstraZeneca • SYBR® I dye DNA staining assay 6 (6.0) 2
• P. falciparum NF54
SJCRH, St Jude’s Children’s Research Hospital; FDA, Food and Drug Administration; GSK, GlaxoSmithKline; HTS, high-throughput screening;
DAPI, 4′,6-diamidino-2-phenylindole.
*Two additional compounds were sourced for in vivo testing, one each from Novartis and Cephalon Inc. In vivo testing was performed only on those compounds
that had an acceptable clinical toxicity/safety/pharmacokinetic profile (or no clinical data). Except for AstraZeneca compounds, which were tested in house, all
in vivo testing was performed by GlaxoSmithKline.
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drugs from other therapeutic areas for testing against P.
falciparum. All 100 candidates had been discontinued
for the original indication, and Phase I/II data were
available for several compounds. AZ verified the samples
for purity and conducted in vitro and in vivo testing for
the compounds.
None of the test sets described above was prescreened
for pharmacokinetics/safety but included in their entirety.
This was because identification of any active compound
could also have led to testing of related follow-up com-
pounds that did not reach clinical testing (and so would
not have been included in the initial test set).
In vitro screening assays
More detailed information on the in vitro methods is
provided in Additional file 1.
SJCRH used the SYBR® I dye DNA staining assay,
which measures proliferation of P. falciparum in human
erythrocytes [27]. Plasmodium falciparum strains 3D7
(chloroquine-sensitive) and K1 (chloroquine-resistant)
(American Type Culture Collection [ATCC], Manassas,
VA, USA) were maintained using established methods
[28]. The assay method is as previously described [29].
Tests were run in triplicate in two independent runs to
generate ten-point, dose–response curves to determine
the half maximal effective concentration (EC50) against
the 3D7 and K1 P. falciparum strains for each drug.
EC50 values were calculated with the robust investigation
of screening experiments (RISE) algorithm with a four-
parameter logistic equation. EC50 values of <1 μM were
considered significant.GSK Tres Cantos used a whole-cell [3H] hypoxanthine
radioisotope incorporation assay to determine per cent
parasite inhibition at 48 hours and 96 hours [30,31].
Plasmodium falciparum 3D7A strain (Malaria Research
and Reference Reagent Resource Center MR4; [32]) was
maintained as described previously [31]. Parasite growth
inhibition assays and EC50 determination were carried
out following standard methods [31]. Three independent
experiments were conducted for each time duration
and test compound. Inactive and active controls were
also included. Parasite inhibition of ≥50% at 48 hours
relative to non-treated parasitized controls was con-
sidered significant.
For the Pfizer STLAR set, initial HTS was performed
by Discovery Biology, Griffith University, Australia using
a 4′,6-diamidino-2-phenylindole (DAPI) DNA imaging
assay [33]. Plasmodium falciparum 3D7 and the Dd2
clone, which has a high propensity to acquire drug
resistance were maintained using standard methods with
some adaptations [28,33]. Inhibition values of treated
wells were calculated relative to the minimum and max-
imum inhibition controls [33]. Inhibition of ≥50% at a
concentration of 0.784 μM was considered significant.
Following the HTS findings, EC50 values were deter-
mined for a subset of active compounds by Pfizer using
a SYBR® I dye DNA staining assay, similar to that
described above for SJCRH, using P. falciparum 3D7
and K1 (both from David Baker, LSHTM). Per cent anti-
malarial activity was calculated relative to the minimum
and maximum controls for each of the 11 drug concen-
trations and EC50 values determined from the resulting
data plot.
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with P. falciparum NF54 (MRA-1000, MR4, ATCC,
Manassas, VA, USA). The per cent inhibition with
respect to the control was plotted against the logarithm
of the drug concentration. The curve was fitted by non-
linear regression using the sigmoidal dose–response
(variable slope) formula to yield the concentration–re-
sponse curves. The concentration at which 50% inhib-
ition was observed was taken as the EC50 value of the
compound. A cytotoxicity assay was also performed by
AZ, using the human hepatoma Hep G2 cell line and
the per cent inhibition and EC50 values were calculated
as described for P. falciparum.
For those compounds showing in vitro activity in any
of the above tests, the available published and unpub-
lished toxicity, clinical safety and human pharmacoki-
netic data were reviewed (due diligence).
In vivo assays
Compounds that showed promising activity in vitro and
that had an acceptable toxicity/safety/pharmacokinetic
profile were progressed to in vivo testing. For the AZ
compound set, a Plasmodium berghei four-day suppres-
sion test was used. For all other compound sets, activity
against P. falciparum in the huSCID mouse was deter-
mined (as described below). Animal experiments complied
with all national and European Union laws, guidelines and
codes of conduct for animal care and research use.
Plasmodium berghei four-day suppression test
AZ compounds were tested by the company for in vivo
efficacy in a standard four-day suppression test using
the rodent malaria parasite P. berghei [34]. All animal
experimentation protocols were approved by the Insti-
tutional Animal Ethics Committee registered with the
Government of India (Registration No: 5/1999/CPCSEA).
Adult male BALB/c mice (purchased from RCC Labora-
tories, Hyderabad, India) were used for efficacy studies.
Animals were randomly distributed to cages quarantined
for one week with veterinary examination and then taken
into experimentation. Feed and water were given ad libi-
tum. Briefly, male BALB/c mice were infected intrape-
ritoneally with 2×107 infected erythrocytes on day 0. Test
compounds were administered orally at a volume of
10 mL/kg as once (UID) or twice daily (BID) doses every
24 hours for four days. On day 3, per cent parasitaemia
was estimated microscopically from a Giemsa-stained
blood smear. The effect of the test compound on parasite
growth was calculated as the difference between the mean
value of the control group (taken as 100%) and those of
the experimental group and expressed as per cent reduc-
tion. Reference anti-malarial compounds (chloroquine
and artemisinin) were used as positive controls and the
results obtained matched those published in the literature.Pharmacokinetics were analysed in healthy as well as
infected mice. Data from healthy mice were used for
designing the dosing regimen for the efficacy studies. In
infected mice, pharmacokinetics was carried out on day 2
of compound administration. One mouse per time point
was sampled according to the fast mouse pharmacokinetic
protocol [35].
Plasmodium falciparum huSCID mouse model
In vivo testing using this model was performed by GSK
at Tres Cantos, against P. falciparum 3D7 (in vivo strain
Pf3D70087/N9generated by GSK using Pf3D7 obtained
from Eduardo Dei-Cas, Institute Pasteur, Lille, France
[36]) growing in peripheral blood of female NOD-scid
IL-2Rγnull mice engrafted with human erythrocytes, i e, a
‘humanized’ mouse model, following published protocols
[36,37]. Briefly, animals were infected intravenously with
20×106 infected erythrocytes on day 0. Test compounds
were administered orally at a volume of 20 mL/kg or
subcutaneously (10 mL/kg) in an appropriate inactive
vehicle. Dosing was initiated at the maximum tolerated
dose in mice on day 3 after infection and continued once
daily for four days. Each experimental group was n = 3
mice unless otherwise stated. Control animals received
vehicle only and a quality control assay used chloroquine
at target doses of 3 mg/kg and 7 mg/kg. Venous blood
samples for parasitology (2 μL) were taken at days 3, 5,
and 7 after infection. Anti-malarial efficacy was assessed
using a standard four-day test (i e, at day 7) and blood
parasitaemia was measured by fluorescence-activated
cell sorting (FACS) analysis [38]. The limit of detection
(per cent of P. falciparum) was 0.01%. The number of
parasites ×106 cells was recorded and data were analysed
by non-linear fitting to a logistic equation of log10 (per
cent parasitaemia at day 7 after infection) versus the
dose level administered.
Per cent parasitaemia at day 7 after infection in treated
versus control animals was analysed using a one factor
ANOVA with Tukey’s post-test analysis. If there was a
significant difference (P < .05) then the ED50 was calcu-
lated as the dose in mg/kg that reduced parasitaemia at
day 7 after infection by 50% with respect to vehicle-
treated mice. ED90 was calculated similarly. Analysis was
performed using WinNonlin 5.2 and GraphPad Prism 5.0.
The pharmacokinetics of compounds after oral admin-
istration was determined concurrently in the same mice
used for the therapeutic efficacy assay. Samples were
taken at 0.25, 0.5, 1, 3, 6, 8, and 24 hours after the first
dose. Compound levels were measured in 25 μL blood
samples that were mixed with 25 μL of saponin (0.1% in
water) and processed under standard liquid–liquid ex-
traction conditions [39]. Pharmacokinetic parameters
were calculated using WinNonlin 5.2 non-compartmental
analysis. The data for the exposure of the drug in blood
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tration and parasitaemia at day 7 were fitted to a logistic
function to predict the exposure necessary to inhibit para-
sitaemia at day 7 after infection in compound-treated mice
by 90% with respect to vehicle-treated mice (AUCED90).
Results
Screening
At SJCRH, screening of approximately 3,800 FDA-
approved drugs and other bio-actives identified 24
compounds with EC50 values <1 μM (Table 2). Of these,
19 had known pharmacokinetic and/or safety profiles
that were considered unsuitable for development as an
oral anti-malarial drug. Of the other compounds, two
are available only for topical/external use (dequalinium,
demecarium); pravastatin cannot be used in pregnancy;
and sulphamerazine is a sulphonamide – a class of
molecule that has already yielded anti-malarial drugs,Table 2 Most active compounds tested by St Jude’s Children’
Compound Class (therapeutic area)
Methylene blue Nitric oxide/guanylate cyclase inhibitor (various)
Dactinomycin Nucleoside reverse transcriptase inhibitor (oncology)
Sulfamerazine Dihydrofolate synthetase inhibitor (anti-infective)
Methotrexate Dihydrofolate reductase inhibitor (oncology)
Bortezomib Proteasome inhibitor (oncology)
Thiothixene Post-synaptic receptor agonista (anti-psychotic)
Dequalinium Anti-septic
Doxorubicin Topoisomerase II inhibitor, DNA intercalating agent (o
Pentamidine Inhibition of DNA, RNA, phospholipid and protein syn
Bosutinib Tyrosine kinase inhibitor (oncology)
Aminopterin Dihydrofolate reductase inhibitor (oncology)
Midostaurin Multi-kinase inhibitor (oncology)
Lestaurtinib FMS-like tyrosine kinase 3 inhibitor (oncology)
Demecarium Cholinesterase inhibitor (ophthalmology)
Cyproterone Steroidal anti-androgen (oncology)
Lapatinib Tyrosine kinase inhibitor (oncology)
Pimozide Dopamine receptor blocker (anti-psychotic)
Pravastatin HMG-CoA reductase inhibitor (anti-cholesterol)
Dipyrone NSAIDb (pain)
Mitomycin Inhibition of DNA synthesis (oncology)
Propafenone Sodium channel modulator (cardiology)
Cyclosporin A Immune suppressant (oncology)
Vorinostat Histone deacetylase inhibitor (oncology)
Sorafenib Multi-kinase inhibitor (oncology)
NA, not available. EC50 values are shown as mean (95% CI). Compounds with an EC
compound sets tested at SJCRH are shown. Where compounds were duplicated acr
are shown. Known anti-malarial drugs have been excluded.
aAgonist of dopaminergic-receptors, serotonergic-receptors, histaminergic-receptors
bMechanism unknown.
SYBR®I fluorescence assay for activity against P. falciparum strains 3D7 and K1.although P. falciparum has developed resistance to the
compounds that are used clinically. Lestaurtinib (CEP-701)
is a protein kinase inhibitor in development by Cephalon
Inc for acute myelogenous leukaemia and myeloprolifera-
tive disorders. Clinical information on this compound was
limited at the time of the study and protein kinase inhibi-
tors have been suggested as an important target in malaria
[9,40,41]. Thus, only lestaurtinib was progressed to the
P. falciparum HuSCID mouse model. These results
mirrored those previously reported by this group [42].
In the GSK discontinued drugs set, 6.4% (4/63) of
compounds tested showed activity greater than 50%
inhibition at a concentration of 2 μM in the [3H] hypo-
xanthine incorporation assay at 48 hours; IC50 values are
shown in Table 3. Upon further evaluation, these four
compounds were not progressed for the following
reasons. Piritrexim is a dihydrofolate reductase inhibitor
and lurtotecan a topoisomerase I inhibitor and neithers Research Hospital
EC50 3D7 (μM) EC50 K1 (μM)
<0.0003 (NA) <0.0003 (NA)
0.0009 (0, 0.13) 0.001 (0.0003, 0.006)
0.01 (0.01, 0.01) 0.01 (0.01, 0.01)
0.01 (0.009, 0.01) 0.02 (0.01, 0.02)
0.02 (0.01, 0.04) 0.08 (0.07, 0.09)
0.04 (0, 233.71) 0.02 (0.01, 0.05)
0.06 (0.002, 1.53) 0.06 (0.03, 0.12)
ncology) 0.21 (0.16, 0.27) 0.20 (0.14, 0.30)
thesisb (anti-infective) 0.22 (0.18, 0.27) 0.05 (0.04, 0.06)
0.22 (0.016, 3.11) 0.65 (0.36, 1.19)
0.32 (0.30, 0.33) 1.25 (1.11, 1.41)
0.35 (0.17, 0.71) 0.15 (0.13, 0.17)
0.49 (0.28, 0.84) 0.34 (0.29, 0.41)
0.51 (0.45, 0.57) 0.30 (0.26, 0.36)
0.56 (0.54, 0.58) 0.89 (0, 1501.50)
0.56 (0.39, 0.80) >7.37 (NA)
0.70 (0.44, 1.11) >12.76 (NA)
0.75 (0.51, 1.09) 0.12 (0.10, 0.15)
0.84 (0.71, 0.98) 0.50 (0.21, 1.16)
0.97 (0.81, 1.17) 0.51 (0.45, 0.57)
1.22 (0.58, 2.55) 0.33 (0.31, 0.34)
1.23 (1.06, 1.44) 0.87 (0.62, 1.23)
1.47 (1.17, 1.84) 0.84 (0.76, 0.93)
2.71 (2.4, 3.1) 0.88 (0.7, 1.1)
50 < 1 μM against either P. falciparum strain are shown. Relevant results from all
oss the consolidated test set, the results with the most potent in vitro activity
, alpha1/alpha2-receptors, and muscarinic (cholinergic) M1/M2-receptors.
Table 3 Most active compounds in vitro from the GlaxoSmithKline discontinued drugs compound set
Compound Class (therapeutic area) IC50 μM
Piritrexim Dihydrofolate reductase inhibitor (oncology) 0.011 ± 0.001
SB-435495 Phospholipase A2-inhibitor (anti-infective/anti-inflammatory) 1.126 ± 0.146
Lurtotecan Topoisomerase I inhibitor (oncology) 0.191 ± 0.062
GSK202405 Muscarinic receptor agonist (asthma) 1.582 ± 0.206
Values are mean of three independent measures.
Study performed by GlaxoSmithKline.
IC50 determination against P. falciparum 3D7A strain using [
3H] hypoxanthine incorporation assay.
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peutic window between inhibition of the parasite and
inhibition of tumor-derived cell lines. GSK202405, a
muscarinic receptor agonist, is delivered via oral inhaler
and has limited oral availability. SB-435495 is a phospho-
lipase A2-inhibitor of the pyrimidone class. Previous work
with this series resulted in the clinical anti-malarial candi-
date GSK-932121, which was stopped in clinical deve-
lopment because of adverse events linked to human
mitochondrial respiration. SB-435495 was, therefore, not
continued because of a poor human/parasite selectivity
window and, after EC50 determination, its in vitro activity
was borderline (1.06 μM).
For the Pfizer STLAR set, the initial HTS reported
>50% activity against P. falciparum 3D7 and Dd2 at the
0.784 μM concentration for 1.7% (3/176) of compounds,
with 13.6% (24/176) having activity ≥90% at a concentra-
tion of 7.84 μM. Further evaluation of 13 of the more
active compounds, identified five with EC50 values <1 μM
against either P. falciparum 3D7 or K1 (Table 4). UK-
112,214 is a dual platelet activating factor receptor/hista-
mine H1 (PAF-H1) receptor antagonist and was selected
for in vivo studies in the P. falciparum mouse model. The
other four compounds were not progressed for the follow-
ing reasons (unpublished data provided by Pfizer Inc):
CP-631992 is a neuropeptide Y5 receptor antagonist
discontinued because of unfavourable animal toxicity
findings; CE-245677 is a TIE2 tyrosine kinase inhibitor
with reports of significant central nervous system adverse
events at human plasma levels of ~1.5 μM; CJ-0231112 is
a bradykinin B2 receptor antagonist and was rejected
based on drug stability issues and the effect of food on
absorption; and AG-024322, a CDK1/2/4/5 inhibitor, wasTable 4 Most active compounds in vitro from the Pfizer STLA
Compound Class (therapeutic area)
UK-112,214 Dual platelet activating factor/histamine H1 receptor an
CP-631992 Neuropeptide Y5 receptor antagonist (obesity)
CE-245677 TIE2 tyrosine kinase inhibitor (oncology)
CJ-0231112 Bradykinin B2 receptor antagonist (pain)
AG-024322 CDK1/2/4/5 inhibitor (oncology)
NA, not available. EC50 values are shown as mean (95% CI). Compounds with an EC
Study performed by Pfizer Inc.
SYBR® I fluorescence assay for activity against P. falciparum strains 3D7 and K1.known to have a narrow therapeutic window in mouse
cancer models and demonstrated poor tolerability in
Phase I studies.
For the AZ set, 6/100 compounds had an EC50 ≤ 1 μM
(Table 5). All six compounds originated from oncology
programmes, mainly targeting human kinases. Of these
six compounds, AZ-4 targeting CDK2 and AZ-5 target-
ing aurora kinase were not progressed further because of
toxicity concerns with these targets incompatible with
an anti-malarial therapy, specifically the essential role of
CDK2 in maintaining genomic stability in mammals and
myelosuppression associated with aurora kinase inhib-
ition [43,44]. AZ-6 was not progressed because of poor
selectivity with respect to HepG2 cytotoxicity. AZ-1 and
AZ-2 are very closely related structurally. AZ-1 targets
the Trk1 potassium transporter and AZ-2 targets JAK2,
though both compounds have potential cardiovascular
issues via hERG regulation. AZ-3 emerged from an on-
cology programme targeting human farnesyl transferase.
AZ-1 and AZ-3 were further investigated for efficacy
against P. berghei with the aim that if the compounds
showed efficacy, they could be considered as starting
points for a lead optimization programme. Pharmacoki-
netic studies guided the selection of the 100 or 200 mg/kg
BID dose used in the in vivo experiments. Oral amino-
benzotriazole 100 mg/kg was administered to inacti-
vate cytochrome P450 metabolism and increase drug
bioavailability. However, both compounds were only
marginally efficacious (50–60% inhibition) at high doses
(100–200 mg/kg BID) (Figure 2). The lack of convincing
efficacy even at high doses coupled with concerns regard-
ing target selectivity and safety led to a halt in the further
investigation of these compounds.R library
EC50 3D7 (μM) EC50 K1 (μM)
tagonist (allergic rhinitis) 0.55 (0.45, 0.65) 0.6 (NA)
0.7 (NA) 0.40 (0.2, 0.6)
1.1 (NA) 0.8 (NA)
0.65 (0.36, 0.94) 0.4 (NA)
0.7 (0.11, 1.29) 0.4 (NA)
50 < 1 μM against either P. falciparum strain are shown.
Table 5 Most active compounds in vitro from the
AstraZeneca discontinued drugs compound set




Status in original indication
AZ-1 Trk1 0.6 10.4 Stopped after GLP toxicity
AZ-2 JAK2 0.1 2.0 Stopped after GLP toxicity
AZ-3 FAR 1.1 11.7 Stopped after Phase II
AZ-4 CDK2 1.2 11.3 Stopped after GLP toxicity
AZ-5 Aurora
kinase 1
0.4 17.1 Stopped after GLP toxicity
AZ-6 CHK1 0.4 0.3 Stopped after GLP toxicity
GLP, good laboratory practice.
Study performed by AstraZeneca.
SYBR® I fluorescence assay for activity against P. falciparum strain NF54 and














































Figure 2 In vivo efficacy of (A) AZ-1 and (B) AZ-3 candidate
drugs in Plasmodium berghei-infected mice. Study performed by
AstraZeneca. Male BALB/c (n = 3) mice infected with P. berghei
intraperitoneally were treated simultaneously with different dose
groups of compounds and controls for four days starting from day
0. The percentage growth inhibition on final day was plotted against
different groups. P values are versus untreated controls.
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The in vivo efficacy of four compounds was determined
against P. falciparum in the humanized mouse model
(Table 6, Figure 3). Two of these (UK-112,214 and les-
taurtinib) were identified in screening and two (CEP-
1347 and PSC-833) were sourced additionally as a result
of findings with related compounds during screening.
The most active agent tested was UK-112,214, a
water soluble PAF-H1 inhibitor identified in the Pfizer
STLAR screen (Figure 4A). UK-112,214 had an ED90
of 131.3 mg/kg (95% CI 112.3, 156.7), oral exposure
was good, and the pharmacokinetic profile appeared
linear within the dosing range (Figure 4B, Table 7).
Exposure data from UK-112,214-treated mice versus
parasitaemia fitted a sigmoid function (coefficient of
determination R2 = .996). The estimated AUCED90 for
UK-112,214 was 111.5 μg · h · mL−1 · day−1 (95% CI 106.6,
121.1) (Table 7). In this model, the ED90 or AUCED90 mark
the limit between P. falciparum net growth (at lower dose
or exposure) or net clearance from peripheral blood
(at higher doses or exposure). Therefore, in order to
achieve net clearance of P. falciparum from peripheral
blood of mice in two cycles of the parasite, a daily expos-
ure higher than the AUCED90 (111.5 μg · h · mL
−1 · day−1)
would be required. A qualitative analysis of the effect of
treatment with 300 mg/kg UK-122,214 using microscopy
and flow cytometry found parasites remaining in periph-
eral blood 48 hours after the start of treatment (Figure 5A).
These showed cytoplasmic condensation, vacuolization of
trophozoites and absence of mature schizonts. At 96 hours
after the start of treatment some pycnotic parasites were
also detected (Figure 5B). These results suggest that UK-
112,214 does not induce fast killing of P. falciparum in
peripheral blood.
Lestaurtinib (CEP-701) is a protein kinase inhibitor
thought to target fibroblast growth factor receptor 1
(FGFR1), fms-like tyrosine kinase 3 (FLT3), tyrosine kinase
A (TrkA) and janus kinase 2 (Jak2). A related compound(CEP-1347) was also provided by Cephalon Inc for testing
in the model. These compounds were tested up to the
maximum tolerated dose. Although there was a trend for
reduced parasitaemia in mice treated with these com-
pounds, the reduction did not reach statistical significance
and ED90 or AUCED90 could not be estimated (Figure 6).
For CEP-1347 in the P. falciparum-infected mice, the
pharmacokinetics after subcutaneous administration in the
studied dose range did not appear to be linear, with similar
values of Cmax and AUC (0–t) after the administration of
Table 6 Therapeutic efficacy of test compounds against Plasmodium falciparum Pf3D70087/N9 in a humanized mouse
model
Compound Target dose (mg/kg)/route ED50 (mg/kg) ED90 (mg/kg) AUCED90 (μg · h · mL
−1 · day−1)
UK-112,214 100, 300 po 80.1 (99.8, 55.1) 131.3 (112.3, 156.7) 111.5 (106.6, 121.1)
CEP-701 10, 30 sc NC NC NC
CEP-1347 10, 30 sc NC NC NC
PSC-833 50, 100, 200 po – >200 >17.33
ED50 and ED90 values are shown as the mean (95% CI). Data was calculated to three decimal places.
NC, not calculated as the percent reduction in parasitaemia was not significantly different from that of the control animals receiving vehicle only.
sc, subcutaneous; po, oral administration.
Study performed by GlaxoSmithKline.
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http://www.malariajournal.com/content/13/1/143the two selected doses (Table 7). The experimental
doses of lestaurtinib were lower than the target ones,
but again, non-linear pharmacokinetic behaviour was ob-
served (Table 7). Note that preclinical studies in mouse
cancer models had shown efficacy at exposures similar to
































Figure 3 Structure of four compounds tested in the Plasmodium falci
Plasmodium berghei-infected mice.An additional compound, PSC-833 (valspodar), was
tested. This is a non-immunosuppressive cyclosporin
derivative developed primarily as a p-glycoprotein in-
hibitor. As cyclosporin had been active during in vitro
screening against P. falciparum but cannot be considered









































































































 80.6 mg/kg (95% CI 55.1 to 99.8)
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Figure 4 Therapeutic efficacy of UK-112,214 against Plasmodium
falciparum Pf3D70087/N9. A) Parasitaemia in peripheral blood of mice
obtained from day 3 to day 7 after infection for UK-112,214 (closed
circles) or chloroquine (open circles). Data are presented as mean of
three mice ± SE for log10[% parasitaemia]. Data for vehicle-treated
animals are denoted by triangles; B) Dose–response relationship for
log10 [% parasitaemia] at day 7 after infection. Study performed
by GlaxoSmithKline.
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http://www.malariajournal.com/content/13/1/143was considered a potential substitute for addressing the
cyclosporin target. This compound was sourced from
Novartis AG, and although it had completed Phase III
studies as an oncology drug, it had been discontinued for
lack of efficacy. Valspodar did not significantly inhibitTable 7 Pharmacokinetics of test compounds in Plasmodium f
Compound Target dose (mg/kg) Cmax (μg/mL) tmax (h
UK-112,214 100 8.61 (0.4) 4.0 (1.7
UK-112,214 300 17.6 (6.4) 3.3 (4.0
CEP-701a 10 0.63 (0.079) 0.78 (0
CEP-701a 30 2.8 (0.84) 4.0 (1.7
CEP-1347b 10 0.83 (0.44) 4.8 (4.0
CEP-1347b 30 0.73 (0.20) 6.0 (NA
PSC-833c 50 1.39 (0.20) 3.30 (1
PSC-833 100 1.01 (0.53) 5.33 (3
PSC-833 200 0.91 (0.47) 2 (0)
NA, not available; DNAUC, dose-normalized value of AUC(0–t).
Values are the mean (SD). Pharmacokinetics were estimated in whole blood after oral
to P. falciparum-infected humanized mice.
aNote that the experimental doses were 6.4 and 15.0 mg/kg (versus target doses of
bNote that the experimental doses were 8.3 and 22.0 mg/kg (versus target doses of
cNote that the experimental dose was 36 mg/kg (versus target dose of 50 mg/kg).
Study performed by GlaxoSmithKline.P. falciparum parasitaemia in vivo (ED90 > 200 mg/kg)
(Table 6). The oral pharmacokinetics in the dose range
studied was non-linear, with similar values of AUC(0–t) for
both dose levels (100 and 200 mg/kg) (Table 7).
In programmes that are currently being conducted in
collaboration with or supported by MMV, a significant
in vivo potency in the humanized mouse model is consid-
ered to be lower than 20 mg/kg. Therefore, none of the
drugs tested met the criteria for further development.
Discussion
Although a large number of approved, investigational
and discontinued drugs were evaluated in this project,
none of the compounds identified with antiplasmodial
activity met the candidate selection criteria warranting
further development. From the approximately 3,800
compounds that were tested by SJCRH, there were 24
with EC50 values <1 μM against P. falciparum – a hit
rate of about 0.6%, which is similar to that obtained
when testing sets of random pharmaceutical diversity.
Within the unregistered compound sets of GSK, Pfizer
and AZ, 15 of the 338 compounds tested showed signifi-
cant in vitro activity – a hit rate of 4.4%. This higher hit
rate in the unregistered compound sets probably reflects
the greater diversity of bio-activity the SJCRH compound
set. The unregistered compounds reflect the focus of
recent pharmaceutical development in the companies
concerned in anti-proliferative, anti-infective and anti-
inflammatory disease, areas likely to have biological over-
lap with processes in the malaria parasite.
Encouragingly, it is clear that a number of different
targets in the malaria parasite can be addressed by existing
drugs. For example, several protein kinase inhibitors
showed in vitro activity against P. falciparum in this study
(bosutinib, midostaurin, lestaurtinib, lapatinib, sorafenib,alciparum-infected humanized mice
) AUC(0–t) (μg · h · mL) DNAUC(0–t) (μg · h · mL
−1 · day−1)
) 72.1 (2.7) 0.859 (0.32)
) 231 (101) 1.03 (0.45)
.38) 2.8 (0.46) 0.44 (0.072)
) 23.8 (6.8) 1.6 (0.47)
) 8.1 (1.8) 0.98 (0.22)
) 9.9 (2.1) 0.45 (0.092)
.2) 12.90 (2.97) 0.36 (0.082)
.05) 12.26 (4.25) 0.13 (0.04)
13.05 (6.05) 0.065 (0.03)
UK-112,214 and PSC-833 or subcutaneous CEP-701 and CEP-1347 administration
10 and 30 mg/kg, respectively).































































































































B) Day 7, 96 h after the first dose 
TE0370_G7N3D7_SYTO.021 TE0370_G8N1D7_SYTO.022 TE0370_G9N3D7_SYTO.027
Figure 5 The effect of UK-112,214 treatment on Plasmodium falciparum Pf3D70087/N9 in vivo at (A) Day 5 and (B) Day 7. Photomicrographs
of peripheral blood smears stained with Giemsa. Lower panels show flow cytometry dot plots from samples of peripheral blood stained with TER-119-
Phycoerythrine (marker of murine erythrocytes) and SYTO-16 (nucleic acid dye). Dots inside the polygonal region represent P. falciparum-infected
human erythrocytes. Study performed by GlaxoSmithKline.
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http://www.malariajournal.com/content/13/1/143and CE-245677). These compounds were of particular
interest as they are essential throughout all stages of the
Plasmodium spp. lifecycle [40,41]. Many protein kinaseinhibitors have been registered or investigated, primarily
for the treatment of cancer, although these drugs have
known toxicities that have discouraged their use in
BA
Figure 6 Therapeutic efficacy of A) lestaurtinib (CEP-701)
and B) CEP-1347 against Plasmodium falciparum Pf3D70087/N9.
Parasitaemia in peripheral blood of mice obtained from day 3 to day
7 after infection, data for vehicle-treated animals are denoted by
triangles. Data are presented as mean of three mice ± SE for log10
[% parasitaemia] except in plot A, where groups labelled with symbols
had two mice (*) or one mouse (♦) at the end of the experiment. Study
performed by GlaxoSmithKline.
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http://www.malariajournal.com/content/13/1/143malaria. Antiretroviral protease inhibitors were also of
interest and tested in this study, though they had relatively
poor in vitro activity. Previous data showed moderate
in vitro activity of saquinavir, nevirapine, ritonavir, nelfi-
navir, amprenavir, and indinavir at clinically relevant
concentrations [46]. However, a recent clinical study in
HIV-infected women from malaria-endemic regions of
sub-Saharan Africa showed no effect of antiretroviral
treatment on the incidence of malaria [47].
Among the licensed products that were active in vitro,
none of the compounds were progressed to the in vivo
model, mainly because of their unfavourable pharmacoki-
netic and/or safety profile for use as an oral anti-malarial.
However, the scope of this study did not include specula-
tion about the clinical safety and pharmacokinetics that
might be discovered should clinical studies in malaria be
conducted. In fact, a number of these compounds have
been investigated further in malaria. Methotrexate has
good activity against P. falciparum and Plasmodium vivaxin vitro, although poor activity in vivo against murine mal-
aria species [48-50]. The assumed toxicity of methotrexate
and other anticancer drugs when used in short-course,
low-dose therapy has been questioned [51]. However, a
recent clinical study of methotrexate in healthy volunteers
failed to achieve sufficient drug exposures for effective
malaria therapy [52]. Methylene blue has also been inves-
tigated clinically for malaria, although it is slow acting and
there are potential haemolytic effects of this compound in
glucose-6-phosphate dehydrogenase-deficient individuals
[53-56]. Bortezomib has confirmed in vitro activity against
P. falciparum [57], although clinically its effect as an
immunosuppressant probably precludes its use in malaria.
Similarly, although cyclosporin A has shown good efficacy
in a murine mouse model [58], its immunosuppressive
effect prevents its repositioning as an anti-malarial.
Of the non-marketed products, four were selected
from the test sets for in vivo evaluation (AZ-1, AZ-3,
UK-112,214, and lestaurtinib) and two further drugs
were sourced directly from their respective patent owners,
CEP-1347 from Cephalon Inc and PSC833 (valspodar)
from Novartis Inc. Of these six compounds, only UK-
112,214 showed significant activity in vivo. UK-112,214 is
a water soluble PAF-H1 inhibitor targeted for use in
allergic inflammatory conditions, such as allergic rhinitis.
This is perhaps an unexpected target as clinical studies of
the role of PAF in the most severe form of malaria,
cerebral malaria, have been inconclusive [59]. However,
astemizole, identified as a promising compound for repo-
sitioning in a previously reported study, is also a PAF-H1
inhibitor [22]. Of interest is that both UK-112,214
and astemizole have chemical structures related to
known anti-malarial drugs of the 4-aminoquinoline class
(Figures 3 and 7) and do not, therefore, represent a new
class of anti-malarial agent. Astemizole was withdrawn
because of cardiovascular adverse events, specifically pro-
longation of the QT interval caused by potent inhibition
of hERG potassium channels [60]. The relative potential
for cardiovascular adverse events with UK-112,214 is so
far unreported, but an independently run hERG assay sug-
gests it may too have a cardiac liability (hERG = 2.8 μM).
The rate of P. falciparum parasite killing with UK-112,214
was slow, though it could potentially have utility as
a combination therapy for the treatment of asexual
P. falciparum should sufficient human exposure levels
be achieved. Unfortunately, there are no human pharma-
cokinetic data on this compound in the public domain,
but single-dose pharmacokinetic data provided by Pfizer
indicate that UK-112,214 at doses from 10 mg to 480 mg
resulted in Cmax values from 14 to 4145 ng/ml.
Safety is the greatest impediment to the repositioning
of existing drugs to treat malaria. Anti-malarial drugs
are taken in possibly many millions of doses every year.
Most importantly, an anti-malarial must be safe in children
Figure 7 Chemical structures of astemizole and the
4-aminoquinoline ring (chloroquine).
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http://www.malariajournal.com/content/13/1/143and pregnant women as these groups are most severely
affected by the disease. Supply to the patient is often
unregulated, self-medication is common and medical
resources may be limited. Thus, patients may not be
monitored for adverse events or be able to access
medical care should these occur.
To achieve the required therapeutic window for an anti-
malarial drug, it should have good oral bio-availability,
potent activity against the parasite and a high specificity
for perturbing parasite metabolic and biochemical pro-
cesses versus those of the host, ie, few and mild adverse
events. These requirements are challenging, particularly
for drugs that have been developed to affect human
disease processes. In general, unless a drug demon-
strates efficacy in malaria at a lower dose than in the
‘parent’ indication, the required therapeutic window cannot
be achieved. Thus, repositioning of clinical compounds
would seem most appropriate when the new use has a
higher tolerance of potential safety signals, such as from
malaria to cancer chemotherapy rather than vice versa.
In fact, anti-malarial drugs have been successfully
repositioned into other therapeutic areas. Classically,
hydroxyl chloroquine has been used to treat inflamma-
tory conditions such as systemic lupus erythematosus,
lupus nephritis and rheumatoid arthritis [61], and may
also have utility in other auto-immune diseases [62].
More recently, investigations have been initiated into the
use of anti-malarial drugs in cancer, for example, for the
sensitization of tumours to enhance the response to con-
ventional treatments [63,64]. Schistosomiasis is anotherindication that is being examined [65]. In particular,
artemisinins appear to have many potential uses in di-
verse indications [66].
Conclusions
In recent years, repositioning of existing drug therapy
has been suggested as a fast track to developing new
anti-malarial medicines [51,67,68]. Studies such as this
are necessary in the continuing efforts to explore all
potential routes in the search for new effective medi-
cines against this devastating disease. However, the
drugs tested in this study did not approach the efficacy
requirements for progression or had known safety issues
preventing their use in malaria. Thus, it is becoming evi-
dent that the development of new drugs for the treatment
of uncomplicated P. falciparum infection will probably
require the design of molecules specifically targeted at the
parasite and pharmacokinetically optimized to provide a
sufficient margin of safety.
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